GH Research (GHRS) Net Income towards Common Stockholders Growth (3y) (2023 - 2025)
GH Research (GHRS) Net Income towards Common Stockholders Growth (3y) (2023 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
723,416.35 Bn |
723,416.32 Bn |
- |
- |
| 2 |
Belite Bio |
57,340.00 Bn |
57,340.00 Bn |
- |
84.25% |
| 3 |
Quantum Biopharma |
19,125.08 Bn |
19,125.08 Bn |
- |
-10.84% |
| 4 |
Legend Biotech |
3,262.00 Bn |
3,261.71 Bn |
242.10 Mn |
26.38% |
| 5 |
Akari Therapeutics |
1,789.67 Bn |
1,789.67 Bn |
- |
-46.86% |
| 6 |
Evaxion A |
1,480.39 Bn |
1,480.37 Bn |
- |
34.98% |
| 7 |
Psyence Biomedical |
241.78 Bn |
241.78 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.54 Bn |
106.29 Bn |
2.59 Bn |
13.80% |
| 9 |
Abivax |
94.26 Bn |
94.26 Bn |
- |
- |
| 10 |
GH Research |
9.73 Bn |
9.63 Bn |
- |
5.19% |
| Date | Value |
|---|
| Dec 31, 2025 |
5.19% |
| Sep 30, 2025 |
-216.79% |
| Jun 30, 2025 |
-210.07% |
| Mar 31, 2025 |
-23.33% |
| Dec 31, 2024 |
-29.10% |
| Sep 30, 2024 |
-87.53% |
| Jun 30, 2024 |
-69.67% |
| Mar 31, 2024 |
-88.26% |
| Dec 31, 2023 |
-226.12% |
| Sep 30, 2023 |
-354.93% |
